Trial Profile
A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Vobarilizumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms STEADY
- Sponsors Ablynx
- 26 Mar 2018 Results presented in an Ablynx Media Release.
- 26 Mar 2018 According to an Ablynx media release, primary endpoint (The percentage of subjects who achieved a response at Week 24 according to the composite m BICLA BILAG-based Combined Lupus Assessment score) has not been met.
- 26 Feb 2018 Status changed to completed.